Merck Raises 2025 EPS & Sales Guidance

Merck revised its 2025 guidance on Oct. 30, 2025, narrowing ranges and raising the midpoint for both EPS and sales. While the company has not published new numerical ranges in the materials provided here, the guidance move is consistent with stronger-than-expected year-to-date operating results. Through nine months of 2025 Merck reported net income of $15,301 million and diluted EPS of $6.07 — gains of +14.3% and +15.4% year over year, respectively — and operating cash flow of $11,259 million. Those metrics provide the cash-earnings foundation that typically allows management to tighten outlook ranges. Operationally, the pharmaceutical portfolio shows mixed dynamics: Keytruda remains the primary revenue driver with $31.68 billion in FY 2025 sales (+7.4%), while Gardasil declined sharply (-39.1%). Emerging product momentum—illustrated by Winrevair's large percentage increase—likely helped offset headwinds in mature vaccine volumes. Management’s decision to raise and narrow guidance appears driven by these intra-portfolio offsets combined with resilient cash generation through the first nine months of the year.

Merck’s balance sheet through Sept. 30, 2025 shows total assets of $129.55 billion and total stockholders’ equity of $51.85 billion. Long-term debt rose to $39.97 billion, reflecting active financing in 2025. Notably, Merck closed a $6.5 billion multi‑series notes offering on Sept. 9, 2025 (maturities 2027–2055), underscoring access to debt markets. Operating cash flow and free cash flow generation remain solid: 9M 2025 operating cash flow totaled $11,259 million with implied free cash flow near $9.7 billion. That cash generation supports dividends, R&D investment and selective deal activity while giving management flexibility when revising guidance.

A raised, narrower outlook is typically positive for investor confidence, but Merck’s profile includes important caveats. Keytruda accounted for 54.5% of pharmaceutical revenue in FY 2025, creating concentration risk if pricing, competition or regulatory forces intensify. The company also faces high regulatory and pricing pressure — including potential Medicare drug-price negotiations — which was identified as a high-severity risk in the company’s risk profile. Gardasil’s steep decline (‑39.1% YoY) highlights product maturity and pricing headwinds in vaccines. Investors should weigh the clearer 2025 near‑term picture against medium‑term execution risks: sustaining growth beyond Keytruda, offsetting vaccine compression, and managing debt-funded investments while preserving cash flow.